Lyfius Pharma Resumes Penicillin-G Production in Kakinada Plant

Lyfius Pharma Private Limited, a fully owned step-down subsidiary of Aurobindo Pharma, has announced the resumption of production at its Penicillin-G manufacturing facility in Kakinada, Andhra Pradesh.

According to the BSE filing, the restart occurs after the Andhra Pradesh Pollution Control Board (APPCB) grants the "Consent to Operate" (CTO). With this result, the company has recovered quickly from the fire event that was reported in April of this year. According to the Medical Dialogues team, the self-ignition of coal is said to have caused the fire that started near the coal crusher area at around 10:00 PM IST. Although some ancillary equipment was damaged in the event, Aurobindo Pharma confirmed that no injuries were reported and that the core manufacturing infrastructure was undamaged.

Also Read: Biological E Secures HPV9 Vaccine Manufacturing for India and Global Tenders

Operations were halted for an estimated 20 to 25 days as a precaution and to allow for the replacement of critical equipment. The business had previously guaranteed that the facility was properly insured and estimated the initial loss from the catastrophe to be about Rs 40 million.

Also Read: Experts Address API Manufacturing Quality at USP Convention 2025

Hyderabad, India is home to the headquarters of Aurobindo Pharma Limited, a comprehensive international pharmaceutical corporation. In more than 150 countries, the company develops, produces, and markets a broad variety of active pharmaceutical ingredients, branded specialty pharmaceuticals, and generic medications. The USFDA, UK MHRA, EDQM, Japan PMDA, World Health Organization, Health Canada, South Africa MCC, and Brazil ANVISA are among the regulatory bodies that have authorized the company's 30 manufacturing practices and packaging facilities. Supported by a robust R&D infrastructure, the company's product portfolio is distributed throughout seven primary therapeutic/product areas, including CNS, anti-retroviral, CVS, antibiotics, gastroenterological, anti-diabetics, and antiallergic.